search
Back to results

Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia

Primary Purpose

Bladder Neck Obstruction, Benign Prostate Hyperplasia

Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
Insertion of Temporary Implantable Nitinol Device (TIND)
Sponsored by
Medi-Tate Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bladder Neck Obstruction focused on measuring BPH, bladder neck obstruction, Bladder neck obstruction secondary to BPH

Eligibility Criteria

50 Years - 95 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

Main IC:

  • Subject signed informed consent prior to the performance of any study procedures.
  • Male with BPH, who are at least 50 years of age and that were diagnosed with BOO.
  • IPSS symptom severity score ≥ 10.
  • Peak urinary flow of < 12 ml/sec
  • No pathology found with kidney US
  • Prostatic urethra length < 30 mm
  • Prostate volume < 35 cc
  • Normal Urinalysis and urine culture.

Exclusion Criteria:

Main EC:

  • Any prior prostate treatment
  • Suspected or proved carcinoma of prostate
  • Urethral stricture
  • Urinary bladder stones
  • Serum prostate specific antigen level > 4 ng/ml (unless proved to be carcinoma free by biopsy).
  • Active urinary tract infection as determined by positive culture, bacterial prostatitis within the past year documented by positive culture.
  • Median prostatic lobe enlargement or a prominent obstructing "ball valve" prostatic lobe.
  • Subject has an interest in future fertility and is not willing to undergo fertility treatments whatsoever.
  • Any serious medical condition likely to impede successful completion of the study

Intraoperative EC:

  • Irregular findings by the implanting physician during the implantation procedure by the cystoscopy that to the best of the implanting physician are exerting non compliance with the exclusion or inclusion criteria and that were not noticed previously during screening

Sites / Locations

  • Meir Medical center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

device

Arm Description

Insertion of Temporary Implantable Nitinol Device (TIND)

Outcomes

Primary Outcome Measures

Device related and unanticipated SAE
Device related and unanticipated SAEs will be followed. No such SAEs are expected.

Secondary Outcome Measures

Reduce at least 3 point in the International Prostate Symptom Score (IPSS) in at least 75% of subjects
Questionnaire of IPSS will be done in each visit.
Increase of maximal urinary peak flow by at least 3 ml/s in at least 75% of subjects
Maximal uroflow will be measured in each visit

Full Information

First Posted
September 14, 2011
Last Updated
December 19, 2018
Sponsor
Medi-Tate Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT01436877
Brief Title
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia
Official Title
One-arm Feasibility and Prospective Pivotal Study to Assess the Safety and Efficacy of MediTate Temporary Implantable Nitinol Device (TIND) in Subjects Presenting Bladder Outlet Obstruction Secondary to BPH
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medi-Tate Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and efficacy of MediTate Temporary Implantable Nitinol Device (TIND) used to alleviate symptoms of Bladder Outlet Obstruction (BOO) secondary to Benign Prostate Hyperplasia (BPH).The TIND is inserted in the bladder neck and prostatic urethra under local anesthesia for few days and taken out some 5 days later in the doctors office.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bladder Neck Obstruction, Benign Prostate Hyperplasia
Keywords
BPH, bladder neck obstruction, Bladder neck obstruction secondary to BPH

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
device
Arm Type
Experimental
Arm Description
Insertion of Temporary Implantable Nitinol Device (TIND)
Intervention Type
Device
Intervention Name(s)
Insertion of Temporary Implantable Nitinol Device (TIND)
Intervention Description
Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
Primary Outcome Measure Information:
Title
Device related and unanticipated SAE
Description
Device related and unanticipated SAEs will be followed. No such SAEs are expected.
Time Frame
At 3 months
Secondary Outcome Measure Information:
Title
Reduce at least 3 point in the International Prostate Symptom Score (IPSS) in at least 75% of subjects
Description
Questionnaire of IPSS will be done in each visit.
Time Frame
At 3 months
Title
Increase of maximal urinary peak flow by at least 3 ml/s in at least 75% of subjects
Description
Maximal uroflow will be measured in each visit
Time Frame
At 3 months

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Main IC: Subject signed informed consent prior to the performance of any study procedures. Male with BPH, who are at least 50 years of age and that were diagnosed with BOO. IPSS symptom severity score ≥ 10. Peak urinary flow of < 12 ml/sec No pathology found with kidney US Prostatic urethra length < 30 mm Prostate volume < 35 cc Normal Urinalysis and urine culture. Exclusion Criteria: Main EC: Any prior prostate treatment Suspected or proved carcinoma of prostate Urethral stricture Urinary bladder stones Serum prostate specific antigen level > 4 ng/ml (unless proved to be carcinoma free by biopsy). Active urinary tract infection as determined by positive culture, bacterial prostatitis within the past year documented by positive culture. Median prostatic lobe enlargement or a prominent obstructing "ball valve" prostatic lobe. Subject has an interest in future fertility and is not willing to undergo fertility treatments whatsoever. Any serious medical condition likely to impede successful completion of the study Intraoperative EC: Irregular findings by the implanting physician during the implantation procedure by the cystoscopy that to the best of the implanting physician are exerting non compliance with the exclusion or inclusion criteria and that were not noticed previously during screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Roy Farfara, MD
Organizational Affiliation
Bnai Zion Medical Center, Haifa, Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
Meir Medical center
City
Kfar Saba
Country
Israel

12. IPD Sharing Statement

Learn more about this trial

Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia

We'll reach out to this number within 24 hrs